Celldex, continuing comeback, adds to early promise for skin disease drug
Bio Pharma Dive
JULY 1, 2022
New study results show the medicine appears as effective, or stronger, than standard care for chronic urticarias, a common condition that drugs from Regeneron and Novartis have struggled to treat
Let's personalize your content